skip to main content

SGLT2 Inhibitors and Gout — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateCrystal ArthropathySGLT2 Inhibitors and GoutSCE Rheumatology

A 55-year-old man with recurrent gout and type 2 diabetes starts empagliflozin for its glycaemic and cardiorenal indications. His urate-lowering and diuretic treatment remain unchanged. Which statement best describes the expected effect of SGLT2 inhibition on serum urate?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Serum urate falls modestly, with increased renal urate excretion associated with glycosuria

SGLT2 inhibitors produce a modest reduction in serum urate, making B correct. Empagliflozin reduced serum urate in EMPA-REG OUTCOME, and meta-analysis confirms a class effect. The uricosuria is associated with glycosuria and altered tubular urate handling; it should not be described simply as direct SGLT2-mediated inhibition of proximal-tubular GLUT9. Although the rise in urinary urate excretion may be transient, the reduction in serum urate can persist, excluding D. Osmotic diuresis does not produce the sustained urate rise proposed in C. These drugs do not directly dissolve monosodium urate crystals, excluding E. Their urate-lowering effect is supplementary: SGLT2 inhibitors are not licensed as gout therapy and should not replace indicated treat-to-target urate-lowering treatment.

Reference: Yang S et al. Serum uric acid reduction through SGLT2 inhibitors: evidence from a systematic review and meta-analysis. Frontiers in Pharmacology. 2025. https://pubmed.ncbi.nlm.nih.gov/40612743/